KPMA exerting to extend tax privilege due for drug R&D.

Published: 2006-04-21 06:57:00

Updated: 2006-04-21 06:57:00

The Korea Pharmaceutical Manufacturers Association (KPMA) is working hard to extend the due period of tax exemption for the drug R&D expenditures, which will expire at the end of this year according to a special tax provision.

Vice chairman Moon Gyeong-tae of KPMA met with an aide to Rep. Chan...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK